The Company believes that demand exists for innovative imaging / treatment centers that focus on improving the diagnostic accuracy of coronary disease detection while at the same time offering non-surgical proven methods of disease reversal and prevention. The Company has the immediate opportunity to secure the name of K. Lance Gould, M.D. in association with their centers. K. Lance Gould has developed a coronary disease reversal and prevention program that is focused on diet and life style changes first and pharmacotherapy second. Dr. Gould has published his findings in the Journal of the American College of Cardiology in 2003.

The Company will approach self insured corporations and demonstrate the ability of the center to save substantial health care dollars while improving the overall health of their workforce. The Company’s self insured corporation report, that was prepared for General Motors, was theoretical only although has since been demonstrated with patient data from Dr. Merhige’s center.

The Company believes that not every referring physician will choose to administer the Gould reversal program. The Company has been able to identify a market niche that will enable them to maintain patient referrals and more importantly capture recurring revenue by patients returning for a second PET exam to access the efficacy of their physician’s disease management program.

Previous research by Merhige and Oliverio published, in abstract form, in the Journal of the American College of Cardiology, supports the Company’s alternative revenue source of PET guided CAD therapy. The research goals were to determine if identifying treatment failure with PET by demonstrating progression of CAD despite lipid lowering therapy predicts adverse clinical events.

The conclusions were:

1. Serial PET MPI with dipyridamole and Rb-82 identifies 22% of patients with progressive CAD despite successful lipid lowering therapy that exceeds NCEP-ATP III guidelines.

2. These patients with progressive CAD identified by PET have a significant 5-fold increase in hard coronary events over short term follow-up, compared with those with CAD arrest or reversal.

3. Reversal or progression of CAD measured by PET MPI did not correlate with changes in fasting levels of Total, LDL, HDL cholesterol or Triglycerides in individual patients.

4. Improvement or worsening of CAD could not be predicted from fasting lipid levels, nor was a level of LDL identified that predicted improvement and lower incident of clinical event.

The conclusions of the study are critical in presenting to referring physicians that patients can’t be managed by cholesterol values alone, especially the comfort from cholesterol reduction. Referring physicians now have a reliable diagnostic test that can assess there ability to tailor medical management in the individual patient. The patient can then be captured for the second PET exam empowering both patient and physician. The patient or physician may choose to enter the Gould program in the unfortunate event that the patient progresses their disease on there second PET.